MASSIV: Mass Assembly Survey with SINFONI in VVDS - II. Kinematics and close environment classification

(Abridged) Processes driving mass assembly are expected to evolve on different timescales along cosmic time. A transition might happen around z ~ 1 as the cosmic star formation rate starts its decrease. Identifying the dynamical nature of galaxies on a representative sample is necessary to infer and compare the mass assembly mechanisms across cosmic time. We present an analysis of the kinematics properties of 50 galaxies with 0.9 < z < 1.6 from the MASSIV sample observed with SINFONI/VLT with 4.5x10^9 Msun < M < 1.7x10^11 Msun and 6 Msun/yr < SFR < 300 Msun/yr. This is the largest sample with 2D-kinematics in this redshift range. We provide a classification based on kinematics as well as on close galaxy environment. We find that 29% of galaxies are experiencing merging or have close companions that may be gravitationally linked. This is placing a lower limit on the fraction of interacting galaxies. We find that at least 44% of the galaxies display ordered rotation whereas at least 35% are non-rotating objects. All rotators except one are compatible with rotation-dominated (Vmax/sigma > 1) systems. Non-rotating objects are mainly small objects (Re < 4 kpc). Combining our sample with other 3D-spectroscopy samples, we find that the local velocity dispersion of the ionized gas component decreases continuously from z ~ 3 to z = 0. The proportion of disks also seems to be increasing in star-forming galaxies when the redshift decreases. The number of interacting galaxies seems to be at a maximum at z ~ 1.2. These results draw a picture in which cold gas accretion may still be efficient at z ~ 1.2 but in which mergers may play a much more significant role at z ~ 1.2 than at higher redshift. From a dynamical point of view, the redshift range 1 < z < 2 therefore appears as a transition period in the galaxy mass assembly process.Comment: 23 pages (+29 maps pages), 7 figures, language corrections and reference updates included, A&A in pres

Increased expression of endothelial lipase in symptomatic and unstable carotid plaques

The aim of this study was to evaluate endothelial lipase (EL) protein expression in advanced human carotid artery plaques (HCAP) with regard to plaque (in)stability and the incidence of symptoms. HCAP were collected from 66 patients undergoing carotid endarterectomy (CEA). The degree of plaque (in)stability was estimated by ultrasound and histology. In HCAP sections, EL expression was determined by immunostaining and the intensity was assessed on a semi-quantitative scale (low: <25%, high: >25% positive cells). Monocytes and macrophages in adjacent HCAP sections were stained with a CD163 specific antibody. High EL staining was more prevalent in histologically unstable plaques (in 33.3% of fibrous plaques, 50% of ulcerated non-complicated plaques and 79.2% of ulcerated complicated plaques; χ2 test, p = 0.004) and in the symptomatic group (70.8 vs. 42.9% in the asymptomatic group; χ2 test, p = 0.028). The majority of EL immunostaining was found in those HCAP regions exhibiting a strong CD163 immunostaining. EL in HCAP might be a marker and/or promoter of plaque instability and HCAP-related symptomatology

Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting

Stent implantation produces a systemic increase of inflammatory markers that correlates with Chlamydophila pneumoniae infection in atherosclerotic plaque. We performed a clinical intervention study to investigate the effect of antibiotic treatment on 6-month follow-up angiographic minimal luminal diameter after stenting. Ninety patients were randomly assigned to oral azithromycin or placebo in a double-blinded and randomized fashion. Medication was initiated 2 weeks before a pre-scheduled stenting procedure and maintained 12 weeks thereafter. Angiographic outcomes were evaluated by a six-month follow-up angiography and laboratorial parameters were accessed by blood sampling 2 weeks before stenting, within the first 24 h after procedure and additional samples after four weeks and 6 months. Minimal luminal diameter (1.76 +/- A 0.56 mm Vs. 1.70 +/- A 0.86 mm; P = 0.7), restenosis rate, diameter stenosis, late loss, and binary restenosis rates were comparable in placebo and azithromycin group in the 6 months follow-up. Serum levels of C-reactive protein presented a three fold significant increase in the control group one day after stenting but did not change in the azithromycin group (8.5 [3.0;16.4] Vs. 2.9 [1.7;6.6]-median [25;75 percentile] P < 0.01). Azithromycin does not improve late angiographic outcomes but attenuates the elevation of C-reactive protein levels after stenting, indicating an anti-inflammatory effect